AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Core Insights - AC Immune SA reported its financial results for Q3 2025, highlighting a strategic focus on high-value assets and advancements in its pipeline for neurodegenerative diseases [2][3][5] Financial Performance - The company had cash resources of CHF 108.5 million as of September 30, 2025, which is expected to fund operations until the end of Q3 2027, excluding potential milestone payments [6][10] - R&D expenses for Q3 2025 were CHF 13.1 million, a decrease from CHF 14.5 million in Q3 2024, primarily due to lower spending on the ACI-24.060 ABATE study [9][10] - The company reported a net loss of CHF 15.9 million for Q3 2025, compared to a net income of CHF 5.5 million in Q3 2024, largely due to the recognition of a CHF 24.6 million milestone in Q3 2024 [10][16] Pipeline and Development - The company is advancing three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau, and alpha-synuclein [3][6][7] - Upcoming milestones include interim results from the VacSYn trial of ACI-7104.056 for Parkinson's disease and the ABATE Phase 2 trial for ACI-24.060 in Alzheimer's disease, both expected in Q4 2025 [8][9] Research and Publications - AC Immune published significant research findings in peer-reviewed journals, including clinical data on ACI-35.030 in eBioMedicine and preclinical data on PET tracers for TDP-43 pathology in Nature Communications [6][7] Corporate Strategy - Following a strategic review, the company has reduced its workforce by approximately 30% to sharpen its investment focus on key assets [7][10] - The appointment of Prof. Catherine Mummery as Chair of the Clinical Advisory Board is aimed at enhancing the company's expertise in dementia clinical trials [7]